The study of oral selenium for alleviating GI complication in patients undergoing pelvic radiation and chemoradiation ( Kerman)

The study of oral selenium for alleviating GI complication in patients undergoing pelvic radiation and chemoradiation

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190303042887N1

Enrollment

Registered

2019-04-04

Start date

2019-03-03

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant neoplasm of pelvis. malignanat neoplasm of pelvic

Interventions

Intervention 1: Intervention group is patients who undergone pelvic radiotherapy and receive oral selenium. This group receive 200 mg selenium ampule every day and before radiotherapy. Control or plac

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing pelvic radiotherapy

Exclusion criteria

Exclusion criteria: Patients who receive pelvic radiotherapy and have renal functions failure Patients who receive pelvic radiotherapy and have GI functions failure

Design outcomes

Primary

Measure	Time frame
Percent of patient under pelvic radiotherapy. Timepoint: concurrent with radiotherapy. Method of measurement: clinical presentation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeed Rajaie Nejad

Kerman University of Medical Sciences

Saidraha2000@yahoo.com+98 34 3211 5810

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026